(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 24.16% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Maxcyte's revenue in 2026 is $34,419,000.On average, 9 Wall Street analysts forecast MXCT's revenue for 2026 to be $4,178,741,033, with the lowest MXCT revenue forecast at $3,885,174,155, and the highest MXCT revenue forecast at $4,569,914,631. On average, 6 Wall Street analysts forecast MXCT's revenue for 2027 to be $5,113,312,043, with the lowest MXCT revenue forecast at $4,388,568,813, and the highest MXCT revenue forecast at $5,745,995,603.
In 2028, MXCT is forecast to generate $7,446,806,034 in revenue, with the lowest revenue forecast at $7,154,732,592 and the highest revenue forecast at $7,665,807,778.